FAST MONEY FEATURES
Get in the post game. Respond to our "Question of the Day" right now.
Missed an episode of Fast Money? Watch the lastest show here.
Grab a pencil because school is in session and the Fast Money traders are teaching class.
Download Fast Money onto your MP3 Player.
Grab this all-in-one application and get recaps of the show sent right to your desktop or blog.
Get your game on with Fast Money gear.
Check out our scrapbook. These "pix" are guaranteed winners.
Sign up and receive a recap email every Friday after the show!
Get advanced information about the next Fast Money.
![]() |
For people struggling with diabetes, the bathroom scale can be the enemy. But a new drug may change all that.
Late results show an experimental Type 2 diabetes drug from Novo Nordisk [NVO
Loading...
()
] called liraglutide
led to greater reduction in blood sugar than Byetta, a rival medication sold by Amylin Pharmaceuticals [AMLN
Loading...
()
] and Eli Lilly [LLY
Loading...
()
].
And equally important -- among patients who completed the two-year trial, 58 percent of them lost an average of 6 pounds.
That's significant because some older diabetes medicines cause weight gain and many patients struggling with diabetes also tend to struggle with their weight.
Sounds like a winner but there are some health concerns. A recent advisory panel to the U.S. Food and Drug Administration was split on whether to recommend liraglutide approval over concern about thyroid tumors found in mice and rats tested with the medicine.
------------
And, as if Byetta needed any more headwinds – the venerable drug may have even more competition on the horizon.
New results show an experimental diabetes drug from GlaxoSmithKline [GSK
Loading...
()
] was also more effective than Byetta in controlling blood sugar.
The Glaxo drug, called Syncria, is entering Phase III testing; and it’s expected to take two to three years to complete.
We'll be watching.
- Your First Move For Tuesday December 2nd
- Trading 2010 - Gadgets
- Web Extra: IBM
- Pops & Drops: Pfizer, Human Genome...
- New Incentive To Improve... Your Home, That Is!
- Vivendi & GE Reach Tentative Deal
- December To Remember?
- Dow Hits News 2009 High
- BREAKING NEWS: GM Chief To Resign
- Halftime Report: Market Flirting With Resistance
______________________________________________________
Got something to to say? Send us an e-mail at and your comment might be posted on the Rapid Recap. If you'd prefer to make a comment but not have it published on our website send those e-mails to .
Trader disclosure: On June 8th, 2009, the following stocks and commodities mentioned or intended to be mentioned on CNBC’s Fast Money were owned by the Fast Money traders; Najarian Owns (BX) Call Spread; Najarian Owns (DELL) Call Spread; Najarian Owns (FCX) Calls & Put Spread; Najarian Owns (INTC) Call Spread; Najarian Owns (MCD) Call Spread; Najarian Owns (MOS) Put Spread; Najarian Owns (PALM) Call Spread; Najarian Owns (WNR); Najarian Owns (ISIS); Terranova Owns (TER), (XBI), (ABT), (RIMM), (BTU), (BRCM), (GENZ); Terranova Owns (MS) & (MS) Calls; Terranova Is Short (FCX) & (FCX) Puts; Terranova Owns (HES) & (HES) Calls; Terranova Owns (XOM) Call Spread ; Terranova Owns (DIS) Call Spread; Terranova Owns (X) & (X) Calls; Terranova Owns (JPM) & (JPM) Calls; Terranova Owns (POT) & (POT) Calls ; Adami Owns (AGU), (C), (GS), (INTC), (BTU), (MSFT), (NUE); Finerman Owns (BAC) Preferred; Finerman's Firm Own (NOK), (PBR), (RIG), (TBT), (WRC), (KFT); Finerman's Firm Owns (BAC) Preferred; Finerman's Firm Owns (WFC) Preferred; Finerman Owns (WFC) Preferred; Finerman's Firm Is Short (BAC)
CNBC.com with wires





